Skip to content

Reducing the acute pain and the need to narcotic pain relievers after cesarean surgery

A comparison of the effects of diclofenac sodium suppositories, intravenous paracetamol and the combination of diclofenac sodium suppositories and intravenous paracetamol on reducing the acute pain and the need to narcotic pain relievers after cesarean surgery under spinal anesthesia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2013022512593N1
Enrollment
99
Registered
2013-12-04
Start date
2013-04-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cesarean surgery. Maternal care for known or suspected malpresentation of fetus

Interventions

Intervention 1: Second group will receive 1 gr intravenous paracetamol in 500 cc normal saline while entering the recovery and then they will receive 3gr intravenous paracetamol via PCA pomp plus one
Treatment - Drugs
Second group will receive 1 gr intravenous paracetamol in 500 cc normal saline while entering the recovery and then they will receive 3gr intravenous paracetamol via PCA pomp plus one placebo supposit
First group will receive 100 mg Diclofenac sodium suppositories when entering the recovery and then they will receive 100 cc Normal saline via PCA pomp.
Third group will receive 1 gr intravenous paracetamol in 500 cc normal saline while entering the recovery and then they will receive 3gr intravenous paracetamol via PCA pomp plus a diclofenac 100 mg s

Sponsors

Ahvaz Jundishapur University of Medical Sciences (AJUMS)
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Being in ASA class 1 or 2; Being in ages between 18-35; Being first or second pregnancy. Exclusion criteria: Having any known allergies and sensitivities, banned from narcotic drugs, paracetamol, and NSAIDs; Hepatic Dysfunction (transaminaze twice than upper limit of normal level); Kidney dysfunction (plasma creatinine higher than 2.5 mg/dl); Smoking or having any previous pulmonary disease; Drug, narcotic, and alcohol abuse; Subjects with the history of depression or chronic anxiety; Subjects experienced the side effects of spinal anesthesia: back pain, radicular pain, paresthesia and hypoesthesia, PDPH; Spinal contraindication; Contraindications for the Use of Spinal Anesthesia (Patient decline, infection in the spot for entering the needle, high intracranial pressure, bleeding susceptibility).

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Patient reported pain level. Timepoint: 1, 4, 12, and 24 hours after surgery. Method of measurement: Visual Analog Scale for Pain (VAS Pain).

Secondary

MeasureTime frame
Intravenous Morphine. Timepoint: in periods of 0-4; 4-12; and 12-24 hours after surgey. Method of measurement: intravenous morphine dose (mg/kg).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Gholamreza Safari Hezarvand

Ahvaz Jundishapur University of Medical Sciences (AJUMS)

safari.r@ajums.ac.irreza.safari79@gmail.com+98 61 1332 3175

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026